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Abstract: Psychiatric disorders and obstructive sleep apnea (OSA) are often comorbid. 
However, there is limited information on the impact of psychotropic medications on OSA 
symptoms, on how to manage psychiatric pharmacotherapy in patients presenting with OSA, 
or on the effectiveness and challenges of OSA treatments in patients with comorbid mental 
illness. As such, the objective of this article is to provide an overview of some epidemiological 
aspects of OSA and treatment considerations in the management of OSA in individuals with 
comorbid psychiatric disorders. Predefined keywords were used to search for relevant literature 
in electronic databases. Data show that OSA is particularly prevalent in patients with psychiatric 
disorders. The medical care that patients with these comorbidities require can be challenging, 
as some of the psychiatric medications used by these patients may exacerbate OSA symptoms. 
As such, continuous positive airway pressure continues to be the first-line treatment, even in 
patients with psychiatric comorbidity. However, more controlled studies are required, particularly 
to determine continuous positive airway pressure compliance in patients with mental illness, 
the impact of treating OSA on psychiatric symptoms, and the impact of the use of psychotropic 
medications on OSA symptoms.
Keywords: obstructive sleep apnea, psychiatric disorders, comorbidity, psychotropic 
medications
Background
Obstructive sleep apnea (OSA) is a clinical syndrome in which a person recurrently 
stops breathing throughout his or her sleep.1 These interruptions in breathing are 
caused by an upper airway obstruction as a consequence of inadequate motor tone of 
the tongue and/or airway dilator muscles. Patients may experience partial (hypopnea) 
or complete (apnea) occlusion of airflow. With each period of apnea that the patient 
experiences, a reduction in blood oxygen levels (hypoxia) occur, causing arousals and 
fragmented sleep. Common symptoms include daytime sleepiness, fatigue, irritability 
and impaired cognitive function which have been linked to an increased risk of motor 
vehicle collisions and work-related injuries.2,3 Furthermore, sleep apnea is associated 
with serious health conditions including obesity, cardiovascular disorders such as 
hypertension, ischemic heart disease, arrhythmia, and heart failure; cerebrovascular 
disease; and endocrine disorders including the metabolic syndrome.4–7
In addition to the serious health conditions previously described, psychiatric 
disorders and OSA are also frequently comorbid, especially with depression.8 It has 
been suggested that the mood disturbance may represent a consequence of sleep apnea; 
but it is also argued that psychiatric disorders and their pharmacological treatment 
may contribute to and promote the development of sleep apneas.9 Medications with 
inhibitory effects on the central nervous system (CNS) such as benzodiazepine recep-
tor agonists, barbiturates, antiepileptic drugs, sedating antidepressants, antihistamines, 
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and opiates, all of which are commonly used in patients with 
psychiatric disorders, may also have an impact on sleep qual-
ity and architecture, and thus can worsen or further exacerbate 
the symptoms of OSA.10,11
However, there is currently a paucity of data evaluating 
the impact of psychotropic medications on OSA symptoms, 
on how to manage psychiatric pharmacotherapy in patients 
presenting with OSA, or on the effectiveness and challenges 
of OSA treatments in patients with comorbid mental illness. 
As such, the objective of this article is to provide an overview 
of some epidemiological aspects of OSA and treatment con-
siderations in the management of OSA in individuals with 
comorbid psychiatric disorders.
Methods
A literature search on PubMed, Medline, Embase, Cochrane 
Database, and International Pharmaceutical Abstracts was 
conducted for relevant English-language articles from 1980 to 
June 2015. The main search keywords included the following: 
[“therapy” OR “treatment” OR “therapeutics”] AND [“sleep 
apnea” OR “obstructive sleep apnea”] AND [“psychiatry” 
OR “psychiatric patients” OR “psychiatric disorders”], and 
[“mental health” OR “mental health patients” OR “mental 
health disorders”]. The search was restricted to review pub-
lications in the adult patient population. Additional articles 
in relation to the treatment of OSA in the psychiatric popu-
lation were obtained by manually searching the guidelines, 
the bibliography of retrieved review articles, and the position 
papers of relevant national or international association Web 
sites. A total of 80 articles were selected for this review.
Risk factors, screening, and diagnosis of 
OSA
The prevalence of OSA is higher in patients who have a 
combination of the following risk factors: obesity, neck larger 
than 17 inches for men or 16 inches for women, male sex, 
age $40 years, large tonsils, or recessed chin.12 Differences 
in the structure and physiological behavior of the upper 
airway, in craniofacial morphology, and in the pattern of fat 
deposition between the sexes have been proposed to account 
for a higher male risk of OSA.13–15 It is imperative that at-risk 
patients be screened and appropriately treated to prevent 
complications, as untreated OSA is currently recognized as 
an independent risk factor for mortality.1
Patients who present with or describe signs and symptoms 
of choking or gasping during sleep, repeated awakenings 
from sleep, unrefreshing sleep, daytime fatigue, and impaired 
concentration should be suspected of having OSA. While 
men often report symptoms such as snoring, waking up 
gasping for air or snorting, many women report symptoms 
like fatigue, anxiety, and depression.15
Because the clinical features are nonspecific and the 
diagnostic accuracy of clinical impression alone is poor, 
a variety of clinical questionnaires and scores have been 
developed to assess patients with common signs and symp-
toms of OSA. The Epworth Sleepiness Scale (ESS), which is 
used to subjectively assess pretreatment sleepiness, is a self-
administered questionnaire that consists of eight scenarios, 
wherein patients rate whether there is a high chance of their 
dozing or falling asleep in that particular situation.16 Another 
validated tool to screen patients for OSA is the STOP and 
the STOP-BANG questionnaires (the latter having a higher 
sensitivity).17 STOP-Bang involves questions pertaining to 
Snoring, Tiredness, Observed apnea, blood Pressure, Body 
mass index, Age, Neck circumference, and Sex.
Depending on level of urgency, which is ranked by suspi-
cion of OSA, the screening score, the individual’s occupation, 
and the presence of comorbidities, most recent guidelines 
recommend polysomnography (PSG) for diagnostic 
testing.14,18,19 The diagnosis of OSA is based on the presence 
or absence of related symptoms, as well as the frequency of 
respiratory events during sleep (ie, apneas, hypopneas, and 
respiratory-effort-related arousals) as measured by a stan-
dardized facility-based PSG. The primary outcome measure 
of PSG is the apnea–hypopnea index (AHI), which is the 
average number of disordered breathing events per hour. 
Typically, OSA is defined as an AHI of 5 or greater with 
associated symptoms (eg, excessive daytime sleepiness, 
fatigue, or impaired cognition) or an AHI of 15 or greater, 
with or without associated symptoms.1,14,20
Management of OSA
Guidelines for the management of OSA recommend 
continuous positive airway pressure (CPAP) as the first treat-
ment of choice.20–22 A CPAP machine provides a constant flow 
of air at a pressure that maintains an open upper airway via a 
mask on either the mouth and/or nose.1,14 When compared with 
controls, CPAP use in patients with moderate and severe OSA 
has shown significant improvements in sleepiness, quality 
of life, cognitive function, and 24-hour blood pressures.23 
Despite its well-recognized benefits, CPAP acceptance and 
adherence remain problematic.1,14,24 Education and support for 
patients who are experiencing difficulties have been reported 
to respond favorably and improve adherence.1,14,24
Other alternative nonpharmacological treatments are oral 
appliances, weight loss, and surgery.25,26 Oral appliances are 
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an alternative for patients with mild-to-moderate OSA who 
are unable to tolerate CPAP therapy.1,14 Appliances exhibit 
their effect by causing displacement of the mandible, which 
expands the diameter of the upper airways.23 Common to all 
guidelines is the recommendation that weight loss should be 
encouraged in all obese patients diagnosed with OSA.21,22,26 
It is important, however, that attempts to lose weight should 
not delay the initiation of CPAP when indicated.21 Surgery 
may also be an option for some OSA patients. The type of 
surgery required varies depending on which particular part 
of the patient’s airway is blocked.25
A number of pharmacological agents have been investi-
gated for the treatment of OSA.27 However, most guidelines 
do not recommend pharmacological agents as first-line 
therapies for OSA.21,22 Nonetheless, the guidelines and a 
few reports also highlight that relief of nasal obstruction and 
agents that promote wakefulness may be useful adjuncts in 
the treatment of patients with OSA to either facilitate treat-
ment with CPAP or help decrease daytime sleepiness despite 
other therapies.14,21,22,28
Comorbidity of OSA in patients with 
mental illness
Overall, the evidence is stronger and is rapidly building for 
an association of OSA with depression and anxiety. In a large 
cohort study of patients with sleep apnea, psychiatric comor-
bidity included depression (21.8%), anxiety (16.7%), post-
traumatic stress disorder (PTSD) (11.9%), psychosis (5.1%), 
and bipolar disorders (3.3%).9 A recently published systematic 
review indicated that there may be an increased prevalence of 
OSA in individuals with major depressive disorder and with 
PTSD.29 Another recent retrospective study found that there 
is a significant increased likelihood of being diagnosed with 
OSA and a mood disorder (odds ratio [OR] =1.85; 95% con-
fidence interval [CI] =1.71–1.72) or an anxiety disorder (OR 
=1.82; 95% CI =1.77–1.84).8 Notably, this positive relation 
remained after accounting for severity of body mass index. 
Other authors have also reported positive correlations between 
anxiety and depression in patients with OSA.30–34
In a systematic review of the literature, Youssef et al 
indicated that the prevalence of OSA in patients with attention 
deficit hyperactivity disorder (ADHD) is higher than in the 
general population, approximately 25%–30% versus 3%, 
respectively.35 In another more recent study, although ADHD 
was not a frequent illness in adult patients with OSA, those 
with OSA and ADHD showed higher levels of anxiety and 
daytime sleepiness and poorer quality of life than in those 
without ADHD.36 Although OSA and insomnia appear to be 
opposing conditions based on the indicators of alertness and 
sleepiness, as pointed out by Luyster et al,37 numerous studies 
have found that these two conditions frequently coexist, with 
39%–54.9% of patients with OSA either meeting criteria for 
insomnia or displaying insomnia symptoms as defined by the 
individual studies.37
There seems to be insufficient evidence to support increased 
OSA in schizophrenia or in bipolar disorder;29 however, indi-
viduals with these conditions are known to be at an increased 
risk for metabolic syndrome and obesity, which are also impor-
tant risk factors for OSA.38–40 Although a causal relationship 
between OSA and Alzheimer’s disease (AD) has not been 
established, in a recent review of the literature, authors indi-
cated that the sleep fragmentation and intermittent hypoxia that 
occurs in OSA could promote cognitive dysfunction, overlap-
ping with that in AD and other neurodegenerative diseases.41
Psychotropic medications and the 
management of OSA
Antipsychotics
OSA is often overlooked in the context of schizophrenia, 
because its hallmark symptom, daytime sleepiness, is so easily 
attributable to antipsychotic medications.38 The use of atypical 
antipsychotics is associated with a near doubling of the risk of 
severe OSA, possibly due to an induction of abnormal upper 
airway tone or alteration in respiratory control secondary to 
dopamine receptor antagonism.42 As obesity is one of the main 
precipitating factors of OSA, medication-induced weight gain, 
a well-known side effect from atypical antipsychotics, can lead 
to worsening or exacerbating OSA symptoms.38 Interestingly, 
Shirani et al found that the use of atypical antipsychotics in 
subjects with depression, but not in those with other psychi-
atric diagnoses, appeared to increase the risk of OSA after 
controlling for known predisposing factors.43
Antidepressants
Various types of antidepressants have been investigated for 
the treatment of OSA, and, as depression has been linked 
with OSA, treatment with a tricyclic antidepressant (TCA), 
selective serotonin receptor inhibitor (SSRI), or another 
form of serotonergic agent may provide benefits for both of 
these diseases. The use of TCAs has been reported to result 
in an approximately 10% decrease in rapid eye movement 
(REM) sleep.10 As apneas tend to more frequently occur in 
REM sleep, a decrease in this stage provides a protective 
mechanism against respiratory-related arousals.10,44 However, 
clinical consequences of REM suppression can be a change 
in frequency and intensity of dreaming, as well as a possible 
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negative effect on memory and learning.44 Protriptyline has 
been the most studied TCA in OSA patients. Three cross-
over studies published in the 1980s comparing protriptyline 
to placebo demonstrated a nonsignificant improvement in 
objective apnea parameters or symptoms.45–47
It has been reported that the levels of serotonin are 
reduced in patients with depression and in certain sleep 
states that can cause augmentation of OSA symptoms.10 
In the management of OSA, SSRIs have been advocated 
to produce a reduction in REM sleep as well as improving 
upper airway dilator tone through an increase in serotonin 
levels.10,48 When compared with protriptyline, fluoxetine 
significantly reduced REM sleep and significantly improved 
the AHI score during non-REM sleep.48 However, there 
were no significant improvements in AHI during REM 
sleep, or in oxygen desaturations and arousals. In another 
placebo crossover trial involving 20 patients, paroxetine 20 
mg taken orally once daily for 6 weeks reduced AHI during 
non-REM sleep (-35%, P=0.003) but showed no signifi-
cant effects on psychopathologic- or OSA-related daytime 
symptoms.49 Interestingly, in another study in patients with 
coronary artery disease, the use of sertraline was ineffective 
in managing depression in patients with OSA.50 However, 
the effects of sertraline on the symptoms of OSA were not 
assessed in this study.
On the basis of these findings that endogenous serotonin 
release in the brainstem promotes upper airway dilation 
during the awake state while peripheral serotonin release at 
5-HT
3 
receptors promotes REM-related apnea, Prasad et al 
tested if using an SSRI (fluoxetine) in combination with 
a medication that inhibits 5-HT
3
 receptors (ondansetron) 
would be advantageous.51 However, patients treated with the 
combination did not report significant improvement in OSA-
related symptoms versus those on placebo. In another study, 
Carley et al investigated whether mirtazapine, a mixed 5HT
2
 
and 5HT
3
 antagonist, would have beneficial effects for OSA 
patients.52 After 1 week of treatment, the mean AHI decreased 
from 22.3 for placebo treatment to 13.5 and 11.4 per hour 
for 4.5 and 15 mg doses, respectively (P,0.004). In addi-
tion, sleep efficiency and REM sleep percentage were 
significantly increased by the 15 mg per day dose (P=0.04). 
Marshall et al further researched the use of mirtazapine in 
OSA by reporting on two separate randomized, double-blind, 
placebo-controlled trials.53 Across both studies, there was no 
significant difference in the amount of time spent asleep or in 
AHI. Additionally, there was a significant increase in weight 
in patients taking mirtazapine across all treatment groups in 
both studies, which may worsen OSA.
Sedative/hypnotics
Benzodiazepines and other sedatives or hypnotics may be 
used for insomnia or anxiety in patients with diverse psy-
chiatric conditions. The use of benzodiazepines in patients 
with OSA has been limited because of their known risk of 
causing reduced upper airway muscle tone and decreased 
ventilatory response to hypoxia, thus potentially increas-
ing the AHI and prolonging apnea events.36,54 If an airway 
obstruction occurs, ventilation is resumed in response to 
CNS arousal that allows the patient to awaken to voluntarily 
dilate the airway. The more sedated the patient is, the more 
difficult it is to rouse and consequently the longer it takes to 
reopen the airway.
Nonbenzodiazepine agents, such as zopiclone, zolpidem, 
and eszopiclone, have hypnotic and sedative effects similar 
to those of benzodiazepines, but some have fewer muscle-
relaxant effects; thus, they may be preferable to use in the 
short-term management of insomnia in OSA.11,36 Studies have 
documented that the use of zolpidem in doses up to 10 mg 
did not impede the use of CPAP in patients with severe OSA; 
however, there was a reduction in sleep latency and mean 
arousal index.55 For this, benzodiazepines and any medication 
that may cause sedation, including opioids or sleeping aids, 
should be used with caution in patients with OSA and should 
be closely monitored, particularly when titrating doses.11 
The short-term use of nonbenzodiazepine agents has been 
advocated through various studies as a safe and effective 
strategy for improving compliance with CPAP in patients 
with comorbid psychiatric disorders.55–57
Stimulants
Psychostimulant medications are associated not only with 
disrupted or disturbed sleep, but also, paradoxically, calm 
some patients with ADHD to sleep by alleviating their 
symptoms.58
Studies using modafinil, a nonamphetamine stimulant 
medication used in the treatment of ADHD, have shown 
significant reduction of excessive daytime sleepiness asso-
ciated with OSA in both objective and subjective measures 
with this medication.59,60 In most guidelines, modafinil is 
recommended for use in patients who have residual daytime 
sleepiness despite optimal use of CPAP.20–22,26,28,61
Despite the aforementioned benefits of modafinil as 
adjunct therapy, its use is associated with some risks, includ-
ing cardiovascular complications, dependency, and abuse 
potential. Heitmann et al studied blood pressure effects of 
modafinil in patients with OSA.62 The effect on blood pres-
sure was not significant between modafinil and placebo, but 
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as this study occurred over a very short period of time, the 
long-term cardiovascular implications require further inves-
tigation. Because of the greater risk of dependency and abuse 
with stimulant medications, they are not recommended for 
the treatment of OSA at this time.20–22
Miscellaneous
As rates of smoking are at least two times higher among 
patients with psychiatric disorders,63 the value of nicotine 
replacement products for patients with both psychiatric dis-
orders and OSA was also researched. Nicotine may improve 
OSA by stimulating respiration and oropharyngeal muscles.64 
A small study of eight patients by Gothe et al found that the use 
of 2 and 4 mg nicotine gum significantly reduced the number 
of apneas, during both the first and second hour of sleep.65 
However, studies looking at other forms of nicotine adminis-
tration, such as transdermal patch, did not show any effect on 
AHI.66 As nicotine acts as a stimulant, it has been reported that 
sleep efficiency and sleep architecture are negatively affected 
in these studies.63,67 Therefore, although smoking cessation 
should be promoted and encouraged among patients with 
mental illness, the use of nicotine strictly for the treatment of 
OSA has not been reported to offer clear benefits.
Of particular importance is the avoidance, or reduction, 
of alcohol intake. Ingestion of alcohol before sleep has been 
shown to increase upper airway collapsibility, therefore, pre-
cipitating obstructive apneas and hypopneas during sleep.67 
The severity of the effects of alcohol on OSA is controver-
sial, likely due to the variation in amounts that patients may 
consume prior to sleep. Peppard et al found that relative 
to men who drank less alcohol, for each increment of one 
drink per day, there was a 25% greater odds of worsened 
episodes of sleep apnea (P=0.006).68 For this reason, avoid-
ance (or moderation if avoidance is not possible) of alcohol 
should be encouraged for patients diagnosed with OSA.
CPAP for the management of OSA in 
patients with mental illness
No controlled studies have exclusively focused on the use 
of CPAP in patients with severe mental illness; however, 
there are case reports describing improvement in both OSA 
and psychiatric symptoms with the use of CPAP in patients 
with schizophrenia.69–71
Unlike in schizophrenia and bipolar disorder, the use of 
CPAP in patients with comorbid depression and/or anxiety 
disorders has been extensively studied. El-Sherbini et al 
found a significant reduction in depressive symptoms as 
determined by the Hamilton Depression Rating Scale and 
improvement in ESS scores (11.6±8.6 to 5.1±3.1) after CPAP 
treatment for 2 months.72 In a recent systematic review of the 
literature and meta-analysis, Povitz et al reported that CPAP 
improved depressive symptoms compared to the control 
intervention (usually sham CPAP) but revealed considerable 
variability between trials.73 Notably, CPAP treatment resulted 
in a greater improvement in depressive symptoms in trials in 
which there was a high prevalence of depression at baseline 
than in trials in which there was a low prevalence of depres-
sion at baseline. CPAP has also been reported to be effective 
in OSA patients with comorbid PTSD, showing reduction 
in PTSD-associated nightmares and improving the overall 
PTSD symptoms.74 Similarly, when it was used in patients 
with panic disorder, CPAP showed positive outcomes in the 
severity and the frequency of panic attacks.56 Likewise, in 
patients with ADHD, Youssef et al investigated the effects 
of CPAP treatment on ADHD and established that in six 
interventional studies, either improvement or resolution of 
ADHD occurred after treatment with CPAP or surgery.34
Krakow et al examined the effect of CPAP, oral appli-
ances, or surgery on sleep measures in patients with chronic 
insomnia and episodes of sleep apnea who completed a 
cognitive behavior therapy program.55 Both treatment phases 
(cognitive behavior therapy alone or in combination with 
OSA treatment of CPAP, oral appliance, or surgery) resulted 
in improvements in insomnia severity and sleep-related 
daytime impairments; however, cognitive behavior therapy 
alone had a small effect on daytime impairments.
The current literature review also revealed only a few 
case reports of CPAP-induced psychiatric relapse, one in a 
previously stable chronic schizophrenic as well as emergent 
manic episodes in patients with bipolar disorder.75,76 As pre-
viously discussed, compliance with CPAP is challenging; 
however, this has not been extensively evaluated in patients 
with psychiatric disorders.29 Some studies have demonstrated 
adequate CPAP compliance in patients with PTSD and 
AD.77,78 Some studies have also reported on the negative influ-
ence of the presence of depression during the CPAP titration 
trial and on the presence of untreated insomnia symptoms on 
CPAP compliance.79,80 However, further studies are needed 
to clarify whether the treatment of depression and insomnia 
symptoms leads to a benefit in CPAP compliance.
Conclusion
OSA is particularly prevalent in patients with psychiat-
ric disorders. The medical care that patients with these 
comorbidities require can be challenging as some of the 
psychiatric medications used by these patients may worsen 
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or exacerbate OSA symptoms. Although pharmacotherapy 
for the management of OSA is available, evidence on their 
efficacy is not robust. As such, CPAP continues to be the first-
line treatment, even in patients with psychiatric comorbidity. 
However, more controlled studies are required, particularly 
to determine CPAP compliance in patients with mental ill-
ness, the impact of treating OSA on psychiatric symptoms, 
and the impact of the use of psychotropic medications on 
OSA symptoms.
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